The drug is still going through trials, but the medical company Lilly, behind it, is hopeful it can be rolled out soon. In recent years, people have turned to weight loss jabs instead to help them lose weight after they were approved for use by UK and US health bodies.

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily weight loss pill, orforglipron, demonstrated effectiveness consistent with other injectable GLP-1 weight loss drugs, such as Lilly’s Mounjaro and Novo Nordisk’s Ozempic.